Page last updated: 2024-09-05

sb 203580 and perfosfamide

sb 203580 has been researched along with perfosfamide in 1 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (perfosfamide)	Trials (perfosfamide)	Recent Studies (post-2010) (perfosfamide)
3,489	4	1,137	328	18	15

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, KL; Li, XF; Luo, J; Niu, HQ; Qin, KL; Zhao, WP; Zhao, XC	1

Other Studies

1 other study(ies) available for sb 203580 and perfosfamide

Article	Year
Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway. International immunopharmacology, 2018, Volume: 61 Topics: Arthritis, Rheumatoid; Cells, Cultured; Cyclophosphamide; Drug Therapy, Combination; Fibroblasts; Gene Expression Regulation; Humans; Imidazoles; Interleukin-6; Janus Kinase 2; Methotrexate; p38 Mitogen-Activated Protein Kinases; Pyridines; RANK Ligand; Receptors, Interleukin-6; Signal Transduction; STAT3 Transcription Factor; Synoviocytes; Tyrphostins	2018

Article

Year

Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway.

International immunopharmacology, 2018, Volume: 61

Topics: Arthritis, Rheumatoid; Cells, Cultured; Cyclophosphamide; Drug Therapy, Combination; Fibroblasts; Gene Expression Regulation; Humans; Imidazoles; Interleukin-6; Janus Kinase 2; Methotrexate; p38 Mitogen-Activated Protein Kinases; Pyridines; RANK Ligand; Receptors, Interleukin-6; Signal Transduction; STAT3 Transcription Factor; Synoviocytes; Tyrphostins

2018